Article

Pediatricians' intention to recommend human papillomavirus (HPV) vaccines to 11- to 12-year-old girls postlicensing.

The Robert Wood Johnson Clinical Scholars Program, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA.
Journal of Adolescent Health (Impact Factor: 2.97). 11/2008; 43(4):408-11. DOI: 10.1016/j.jadohealth.2008.06.012
Source: PubMed

ABSTRACT We surveyed 105 pediatric clinicians following Human papillomavirus (HPV) vaccine licensure to identify factors associated with intention to recommend the vaccine to 11- to 12-year-old girls. Pediatricians who were early adopters of medical technologies had fewer concerns about HPV vaccine safety/efficacy, and who anticipated parental vaccine safety/efficacy concerns reported higher intention to recommend the vaccine.

0 Bookmarks
 · 
51 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: To compare physician practices, attitudes, and barriers toward human papillomavirus (HPV) vaccination. A Web-based survey that assessed the practice of HPV vaccination, perceived barriers, and opinions of potential vaccine effects was distributed to obstetrician/gynecologists, internists, and pediatricians within a single health care system. A total of 1,488 physicians located in tertiary, community, and private settings were sent the survey. Data were analyzed using multivariate logistic regression. A total of 424 (28.9%) of 1,488 physicians participated. Of these physicians, 80% offer the vaccine. Female, primary care, and community and private practice physicians were associated with increased vaccination, compared with male, subspecialty, and tertiary care physicians, respectively. Physicians who reported no barriers to vaccination were more likely to offer the vaccine (odds ratio = 1.74, 95% CI = 1.04-2.93, p =.04). The greatest barrier to vaccination was reimbursement concerns. Most physicians offer the HPV vaccine. Addressing barriers to vaccination and resolving practical concerns may increase HPV vaccination.
    Journal of Lower Genital Tract Disease 10/2010; 14(4):339-45. · 1.21 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Two human papillomavirus vaccines were licenced in 2006/2007 for cervical cancer prevention. National vaccination programmes for schoolgirls were subsequently introduced in some European countries, North America and Australia. To understand factors influencing vaccine uptake and to inform the development of appropriate UK educational materials, we aimed to synthesise evidence of girls' and parents' information needs, views and preferences regarding HPV vaccination. Systematic review and mixed method synthesis of qualitative and survey data. 12 electronic databases; bibliographies of included studies 1980 to August 2011. Two reviewers independently screened papers and appraised study quality. Studies were synthesised collaboratively using framework methods for qualitative data, and survey results integrated where they supported, contrasted or added to the themes identified. Twenty-eight qualitative studies and 44 surveys were included. Where vaccination was offered, uptake was high. Intention to decline was related to a preference for vaccinating later to avoid appearing to condone early sexual activity, concerns about vaccine safety and low perception of risk of HPV infection. Knowledge was poor and there were many misconceptions; participants tried to assess the potential benefits and harms of vaccination but struggled to interpret limited information about HPV in the context of existing knowledge about sexually transmitted infections and cancer. Conclusion Many girls and their parents have limited understanding to an extent that impinges on their ability to make informed choices about HPV vaccination and could impact on future uptake of cervical screening. This is a considerable challenge to those who design and provide information, but getting the messages right for this programme could help in developing patient information about other HPV related cancers.
    Vaccine 09/2013; · 3.77 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: BACKGROUND: Cervical cancer (CC) is almost always induced by some oncogenic types of human papillomavirus (HPV). In Vietnam, it is the first leading cause of cancer in women, with highest prevalence in Ho Chi Minh City (HCMC). Since 2006, prevention of the CC has been improved by licensure of recombinant vaccines directed against HPV 16 and 18, effective when administered before the age of first sexual intercourse. A national program for routine immunization of pre-adolescent girls in addition to cytological screening of adult women would greatly reduce the impact of CC in Vietnam but vaccines remain expensive and it is unclear how this strategy would be accepted by the target population. The aim of this study was to assess the acceptability of HPV vaccination by pediatricians, mothers with a daughter aged 9-15years and young women aged 16-26years in HCMC. METHODS: Between March and June 2010, a cross-sectional survey of knowledge and attitudes was administered to 115 pediatricians in the pediatric hospital, 210 mothers and 400 young women attending the gynecology department of the University Hospital. RESULTS: Pediatricians generally had a good perception of the risk but they still lacked knowledge about HPV vaccination, given by 66% of them. Among mothers, 18% knew the relationship between HPV infection and CC, 43% had heard of HPV vaccination and 40% agreed to vaccinate their daughter. Among young women, 35% knew the risk, 49% knew the vaccine and 38% wanted to be vaccinated. Level of education, amount of income and celibacy were positively related to intention to be vaccinated. The lack of information on HPV vaccination and the high cost of vaccines were the main causes of refusal or indecision. CONCLUSION: Routine HPV vaccination of girls in HCMC will be well accepted by the population if a large campaign of health education is implemented by the government and if the affordability of vaccines is facilitated.
    Revue d Épidémiologie et de Santé Publique 11/2012; · 0.69 Impact Factor